We are analyzing https://link.springer.com/article/10.1186/s12967-019-1804-8.

Title:
How mRNA therapeutics are entering the monoclonal antibody field | Journal of Translational Medicine
Description:
In 1975, Milstein and Köhler revolutionized the medical world with the development of the hybridoma technique to produce monoclonal antibodies. Since then, monoclonal antibodies have entered almost every branch of biomedical research. Antibodies are now used as frontline therapeutics in highly divergent indications, ranging from autoimmune disease over allergic asthma to cancer. Wider accessibility and implementation of antibody-based therapeutics is however hindered by manufacturing challenges and high development costs inherent to protein-based drugs. For these reasons, alternative ways are being pursued to produce and deliver antibodies more cost-effectively without hampering safety. Over the past decade, messenger RNA (mRNA) based drugs have emerged as a highly appealing new class of biologics that can be used to encode any protein of interest directly in vivo. Whereas current clinical efforts to use mRNA as a drug are mainly situated at the level of prophylactic and therapeutic vaccination, three recent preclinical studies have addressed the feasibility of using mRNA to encode therapeutic antibodies directly in vivo. Here, we highlight the potential of mRNA-based approaches to solve several of the issues associated with antibodies produced and delivered in protein format. Nonetheless, we also identify key hurdles that mRNA-based approaches still need to take to fulfill this potential and ultimately replace the current protein antibody format.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,642,828 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure if the website is profiting.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

mrna, pubmed, article, google, scholar, cas, antibody, protein, rna, delivery, antibodies, central, cells, encoding, therapeutic, ivt, expression, therapy, cell, based, mab, clinical, nucleic, production, gene, therapeutics, dna, mol, mabs, injection, lipid, monoclonal, development, lnps, van, high, vaccines, modifications, immune, activation, ther, vivo, studies, optimized, vitro, field, cancer, vaccination, immunogenicity, administration,

Topics {✒️}

rig-i-mediated antiviral responses t-cell-engaging antibody blinatumomab article download pdf lien van hoecke designed zinc-finger nucleases high-performance liquid chromatography extracellular enzyme-mediated degradation broadly neutralizing antibody anti-respiratory syncytial virus prolonged leukemia-free survival intrinsic immune-stimulatory activity retinoic acid-inducible gene anti-antibody immune responses org/products/monoclonal-antibodies-approved complement activation-related pseudoallergy biodegradable amino-ester nanomaterials dna-encoded antibody prophylaxis t-cell stimulatory capacity n-terminal glutamine cyclization cis-acting structural elements c-terminal lysine processing long-term immunity elicited acute lymphoblastic leukemia immunostimulating single-stranded rna dna-based therapeutics sparked natural post-translational modifications short extracellular half-life pdna-encoded antibody designs peer-reviewed publication showing gene gun-based administration messenger rna-based vaccines mab-encoding nucleotide sequences anti-pathogen therapy anti-toxin therapy mrna-encoded antibodies enables respiratory syncytial virus sequence-engineered mrna cas cutting protein anti-tumor therapy gen replacement therapy particle-mediated intravenous delivery stabilized plasmid-lipid particles cap-dependent protein synthesis receptor-mediated endocytosis nucleic acid therapeutics target-specific mrna optimizations recombinant bispecific antibody 30 µg mrna-lnp encoding produce anti-peg antibodies nucleic acid sensing

Schema {🗺️}

WebPage:
      mainEntity:
         headline:How mRNA therapeutics are entering the monoclonal antibody field
         description:In 1975, Milstein and Köhler revolutionized the medical world with the development of the hybridoma technique to produce monoclonal antibodies. Since then, monoclonal antibodies have entered almost every branch of biomedical research. Antibodies are now used as frontline therapeutics in highly divergent indications, ranging from autoimmune disease over allergic asthma to cancer. Wider accessibility and implementation of antibody-based therapeutics is however hindered by manufacturing challenges and high development costs inherent to protein-based drugs. For these reasons, alternative ways are being pursued to produce and deliver antibodies more cost-effectively without hampering safety. Over the past decade, messenger RNA (mRNA) based drugs have emerged as a highly appealing new class of biologics that can be used to encode any protein of interest directly in vivo. Whereas current clinical efforts to use mRNA as a drug are mainly situated at the level of prophylactic and therapeutic vaccination, three recent preclinical studies have addressed the feasibility of using mRNA to encode therapeutic antibodies directly in vivo. Here, we highlight the potential of mRNA-based approaches to solve several of the issues associated with antibodies produced and delivered in protein format. Nonetheless, we also identify key hurdles that mRNA-based approaches still need to take to fulfill this potential and ultimately replace the current protein antibody format.
         datePublished:2019-02-22T00:00:00Z
         dateModified:2019-02-22T00:00:00Z
         pageStart:1
         pageEnd:14
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s12967-019-1804-8
         keywords:
            mRNA
            mRNA therapeutic
            Antibody therapy
            Passive immunization
            mRNA design
            mRNA technology
            Biomedicine
            general
            Medicine/Public Health
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-019-1804-8/MediaObjects/12967_2019_1804_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-019-1804-8/MediaObjects/12967_2019_1804_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-019-1804-8/MediaObjects/12967_2019_1804_Fig3_HTML.png
         isPartOf:
            name:Journal of Translational Medicine
            issn:
               1479-5876
            volumeNumber:17
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Lien Van Hoecke
               url:http://orcid.org/0000-0001-8602-4211
               affiliation:
                     name:VIB Center for Medical Biotechnology, VIB
                     address:
                        name:VIB Center for Medical Biotechnology, VIB, Ghent, Belgium
                        type:PostalAddress
                     type:Organization
                     name:Ghent University
                     address:
                        name:Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Kenny Roose
               affiliation:
                     name:VIB Center for Medical Biotechnology, VIB
                     address:
                        name:VIB Center for Medical Biotechnology, VIB, Ghent, Belgium
                        type:PostalAddress
                     type:Organization
                     name:Ghent University
                     address:
                        name:Departement of Biochemistry and Microbiology, Ghent University, Ghent, Belgium
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:How mRNA therapeutics are entering the monoclonal antibody field
      description:In 1975, Milstein and Köhler revolutionized the medical world with the development of the hybridoma technique to produce monoclonal antibodies. Since then, monoclonal antibodies have entered almost every branch of biomedical research. Antibodies are now used as frontline therapeutics in highly divergent indications, ranging from autoimmune disease over allergic asthma to cancer. Wider accessibility and implementation of antibody-based therapeutics is however hindered by manufacturing challenges and high development costs inherent to protein-based drugs. For these reasons, alternative ways are being pursued to produce and deliver antibodies more cost-effectively without hampering safety. Over the past decade, messenger RNA (mRNA) based drugs have emerged as a highly appealing new class of biologics that can be used to encode any protein of interest directly in vivo. Whereas current clinical efforts to use mRNA as a drug are mainly situated at the level of prophylactic and therapeutic vaccination, three recent preclinical studies have addressed the feasibility of using mRNA to encode therapeutic antibodies directly in vivo. Here, we highlight the potential of mRNA-based approaches to solve several of the issues associated with antibodies produced and delivered in protein format. Nonetheless, we also identify key hurdles that mRNA-based approaches still need to take to fulfill this potential and ultimately replace the current protein antibody format.
      datePublished:2019-02-22T00:00:00Z
      dateModified:2019-02-22T00:00:00Z
      pageStart:1
      pageEnd:14
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s12967-019-1804-8
      keywords:
         mRNA
         mRNA therapeutic
         Antibody therapy
         Passive immunization
         mRNA design
         mRNA technology
         Biomedicine
         general
         Medicine/Public Health
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-019-1804-8/MediaObjects/12967_2019_1804_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-019-1804-8/MediaObjects/12967_2019_1804_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-019-1804-8/MediaObjects/12967_2019_1804_Fig3_HTML.png
      isPartOf:
         name:Journal of Translational Medicine
         issn:
            1479-5876
         volumeNumber:17
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Lien Van Hoecke
            url:http://orcid.org/0000-0001-8602-4211
            affiliation:
                  name:VIB Center for Medical Biotechnology, VIB
                  address:
                     name:VIB Center for Medical Biotechnology, VIB, Ghent, Belgium
                     type:PostalAddress
                  type:Organization
                  name:Ghent University
                  address:
                     name:Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Kenny Roose
            affiliation:
                  name:VIB Center for Medical Biotechnology, VIB
                  address:
                     name:VIB Center for Medical Biotechnology, VIB, Ghent, Belgium
                     type:PostalAddress
                  type:Organization
                  name:Ghent University
                  address:
                     name:Departement of Biochemistry and Microbiology, Ghent University, Ghent, Belgium
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Journal of Translational Medicine
      issn:
         1479-5876
      volumeNumber:17
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:VIB Center for Medical Biotechnology, VIB
      address:
         name:VIB Center for Medical Biotechnology, VIB, Ghent, Belgium
         type:PostalAddress
      name:Ghent University
      address:
         name:Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium
         type:PostalAddress
      name:VIB Center for Medical Biotechnology, VIB
      address:
         name:VIB Center for Medical Biotechnology, VIB, Ghent, Belgium
         type:PostalAddress
      name:Ghent University
      address:
         name:Departement of Biochemistry and Microbiology, Ghent University, Ghent, Belgium
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Lien Van Hoecke
      url:http://orcid.org/0000-0001-8602-4211
      affiliation:
            name:VIB Center for Medical Biotechnology, VIB
            address:
               name:VIB Center for Medical Biotechnology, VIB, Ghent, Belgium
               type:PostalAddress
            type:Organization
            name:Ghent University
            address:
               name:Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Kenny Roose
      affiliation:
            name:VIB Center for Medical Biotechnology, VIB
            address:
               name:VIB Center for Medical Biotechnology, VIB, Ghent, Belgium
               type:PostalAddress
            type:Organization
            name:Ghent University
            address:
               name:Departement of Biochemistry and Microbiology, Ghent University, Ghent, Belgium
               type:PostalAddress
            type:Organization
PostalAddress:
      name:VIB Center for Medical Biotechnology, VIB, Ghent, Belgium
      name:Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium
      name:VIB Center for Medical Biotechnology, VIB, Ghent, Belgium
      name:Departement of Biochemistry and Microbiology, Ghent University, Ghent, Belgium

External Links {🔗}(372)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Particles.js
Prism.js

CDN Services {📦}

Crossref

5.71s.

LINK . SPRINGER . COM {}